D-tagatose

WEST PALM BEACH, Fla., March 11, 2024 /PRNewswire/ -- Tagatose, a monosaccharide that has gained popularity for its ability to meet calorie-reduction targets without compromising taste, texture or function, is now the first sweetener to attain the NutraStrong™ Prebiotic Verified certification. Continue Reading Tagatose Bonumose, Inc., a producer of tagatose, and ASR Group, its distributor, are proud to announce that tagatose is also the first ingredient to earn this prebiotic certification. This independent endorsement further establishes tagatose as an ideal ingredient for food, beverage and nutraceutical manufacturers seeking sweetener solutions that meet consumer demand for functional, lower-calorie products. As the global appetite for improved gut health continues to grow, demand for prebiotics is increasing because of the important role they play in nourishing beneficial gut bacteria and promoting digestive health. In fact, according to Innova Market Insights, new product launches featuring prebiotic ingredients enjoyed a 6% CAGR between 2017-2023. "Today's consumers want their foods and beverages to work harder for them, so it's no surprise they're seeking prebiotic ingredients," said Karen Weikel, Ph.D., Director of Nutrition Science at Bonumose. "Tagatose is a revolutionary product, because for the first time, we can offer manufacturers a sweetener solution that provides prebiotic benefits, while maintaining the sweetness consumers desire." NutraStrong™ Prebiotic Verified is an industry-spanning program that classifies products with relevant and specific standards for each product category. These standards set a baseline of quality and testing to ensure the market is providing customers with quality prebiotic products. "Bonumose's commitment to both the quality and science required for prebiotic certification serve as an example for the industry," said Kevin Yan, Vice President of Certifications and Analytics at SGS Nutrasource, the company that administers NutraStrong™ certification. "By becoming a certified ingredient, Bonumose gained access to the Prebiotic Certified program for all products utilizing their tagatose. This access gives brands the ability to certify and promote their own usage of tagatose, highlighting the benefits of such quality ingredients." "When the Global Prebiotic Association conceived of the Prebiotic Verified program as part of the NutraStrong™ umbrella, it was to create a reward for suppliers and brands with substantiated prebiotic products - those that invested in quality and science and those that formulated wisely," said Len Monheit, Executive Director of the Global Prebiotic Association. "We are truly excited that the inaugural ingredient through the program is tagatose and that the NutraStrong™ Prebiotic Verified program now includes an ingredient that brands can leverage." Tagatose's prebiotic properties are just one of the many benefits it provides to manufacturers. Compared to sucrose, tagatose is 90% as sweet with 60% fewer calories. It tastes and performs similar to sucrose across a wide variety of applications. Because it has a low glycemic index of 3, tagatose does not raise blood glucose levels when consumed on its own. It is also Ketogenic Certified, Non-GMO Project Verified and Plant-Based Certified. "We believe it's important to provide manufacturers with a variety of sweeteners to meet all of their needs," said Jim Kappas, Vice President of Specialty Ingredients at ASR Group. "Tagatose is a fitting solution for manufacturers who seek to make every calorie count with ingredients that taste great and provide functional benefits." ASR Group will be exhibiting at Natural Products Expo West 2024, March 13-16 in Anaheim, Calif. Attendees interested in learning more about the benefits of tagatose and sampling gummies made with tagatose can visit ASR Group at booth #1013. To learn more about tagatose, visit . Customers may request tagatose samples via this online form. Please contact Lisa Ptak at [email protected] to schedule appointments with ASR Group at Natural Products Expo West. About ASR Group ASR Group International, Inc. (ASR Group) is the world's largest refiner and marketer of cane sugar, with an annual production capacity of more than 6 million tons of sugar. The company produces a full line of grocery, industrial, food service and specialty sweetener products. Across North America, ASR Group owns and operates six sugar refineries, located in New York, California, Maryland, Louisiana, Canada and Mexico. In Europe, the company owns and operates sugar refineries in the United Kingdom, Portugal, and, with a joint venture partner, Italy. ASR Group also farms sugarcane and owns sugar mills in Mexico and Belize. The company's portfolio includes the leading brands Domino®, C&H®, Florida Crystals®, Redpath®, Tate & Lyle®, Lyle's®, Sidul® and Tellus®. ASR Group is owned by Florida-based cane sugar producers Florida Crystals Corporation and Sugar Cane Growers Cooperative of Florida. ASR Group and its parent companies jointly own Tellus Products, LLC, a maker of single-use, compostable tableware and foodservice products from sugarcane and other plant fibers. For more information, visit . About Bonumose, Inc. Bonumose, Inc. ( ) is an early-stage food ingredient and enzyme innovation company based in Albemarle County, Virginia. Bonumose is supported by global strategic investors and "food for health"-focused institutional investors, and an expanding network of global collaboration partners across the value chain. Bonumose developed and patented the methods for continuous production of high-purity rare sugars – such as Tagatose and Allulose – from low-cost, plant-based starch. Bonumose's cost-advantaged processes make possible the global mass-market adoption of healthy, great-tasting, fully-functional rare sugars. Bonumose also can upcycle by-product/sidestream starch left over from its supply chain partners' food production. Beyond food ingredients, Bonumose also is developing enzyme solutions for dietary supplements, crop protection, animal nutrition, and other globally-significant industries. Bonumose operates with a philosophy of Business as a Moral Imperative. About SGS Nutrasource Pharmaceutical and Nutraceutical Services Inc. SGS Nutrasource is a leading nutraceutical and pharmaceutical life sciences company focused on helping clients commercialize health and wellness products. In addition to a unique offering of clinical trial management, strategic and regulatory support services along with a state-of-the-art clinical trial site, SGS Nutrasource offers a series of third-party natural ingredient product certification programs (NutraStrong™, IFOS™, IKOS™, IGEN™, and IPRO™. SOURCE ASR Group

Tate & Lyle and Cryptobiotix's breakthrough ex-vivo* study shows that sucralose does not impact the gut microbiota, while other low and no calorie sweeteners have potentially beneficial health effects LONDON, Feb. 15, 2024 /PRNewswire/ - A new, first-of-its-kind study has identified unique and potentially beneficial interactions between certain low and no calorie sweeteners, including stevia, and the human gut microbiota. Tate & Lyle PLC (Tate & Lyle), a world leader in ingredient solutions for healthier food and drink, partnered with Cryptobiotix, pioneers in preclinical gastrointestinal research, on the study. Continue Reading Tate & Lyle and Cryptobiotix’s breakthrough ex-vivo study shows that sucralose does not impact the gut microbiota, while other low and no calorie sweeteners have potentially beneficial health effects (CNW Group/Tate & Lyle North America) Tate & Lyle and Cryptobiotix’s breakthrough ex-vivo study shows that sucralose does not impact the gut microbiota, while other low and no calorie sweeteners have potentially beneficial health effects (CNW Group/Tate & Lyle North America) Dr. Davide Risso, molecular biology specialist and Tate & Lyle's Head of Nutrition Research, led the project to explore the potential impact of certain low and no calorie sweeteners on the gut environment in both healthy individuals and those with type 2 diabetes. The research involved taking samples from co-living adults consuming a similar diet – to lower the potential variation introduced by differences in long-term diet, a major driver of microbiota composition. The doses of low and no calorie sweeteners used were based on actual intakes, regulations and amounts that are generally included in foods and beverages during different timepoints. Results from the pre-clinical study, published in the leading peer reviewed, open-access journal the International Journal of Food Sciences and Nutrition, found that some of the studied low calorie and no calorie sweeteners had no impact on the gut microbiota, while others had potential beneficial health effects. Using Cryptobiotix's cutting-edge SIFR® ("cipher") technology to recreate the gut environment outside of the human body, the research partners found that sweeteners, such as sucralose, do not impact the microbial composition of the gut. Furthermore, other sweeteners, including stevia, have a beneficial impact on the gut microbiota as they were found to be easily fermented and increase the density of certain health-supporting bacteria, with the production of short-chain fatty acids. The study adds to the strong scientific evidence demonstrating the beneficial role low and no calorie sweeteners can play when used as a part of a balanced diet. Assessments of additional low and no calorie sweeteners, including allulose and erythritol, are being completed and details will be shared in due course. Dr. Davide Risso, Tate & Lyle's Head of Nutrition Research, said: "In this study, the low and no calorie sweeteners we have assessed are shown to have either no impact on the gut microbiota or to offer potential health benefits beyond their established sugar and calorie reduction benefits. Human clinical trials will be required to confirm the potential health benefits. At Tate & Lyle, we're committed to advancing understanding around the role of low and no calorie sweeteners in the diet and sharing knowledge in this emerging field as a purpose-led, science-driven company." Dr Pieter Van den Abbeele, Cryptobiotix's Chief Scientific Officer, said: "Cryptobiotix was founded with the ambition of providing accurate insights into the impact and behaviour of ingredients in relation to the gut microbiome. This study provides much-needed evidence to consider the potential benefits of sweeteners individually, rather than as a uniform whole. The robustness and validation work that went into the SIFR® technology used, allowed us to pinpoint specific health-promoting pathways in relation to specific low and no calorie sweeteners." *In ex vivo studies, living tissues are directly taken from a living organism and studied in a laboratory with minimal alterations to the organism's natural conditions. Notes to editors: The International Journal of Food Sciences and Nutrition article is available here The low and no calorie sweeteners studied for this paper included: Acesulfame potassium (aceK), maltitol, sorbitol, stevia, sucralose and tagatose. 12 individuals were included in the study, a representative cohort for this type of study. Furthermore, candidates from the same households were selected to minimise the effect of environmental variables, such as diet. Dr Davide Risso research profile Dr Pieter Van den Abbeele research profile See other sweeteners research on the Tate & Lyle Nutrition Centre: Click here to access Tate & Lyle's press gallery About Tate & Lyle: Supported by our 160-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients every day. Through our expertise in sweetening, fortification, and texture, we develop ingredient solutions which reduce sugar, calories, and fat, add fibre and protein, and provide texture and stability in categories including beverages, dairy, bakery, snacks, soups, sauces, and dressings. We have more than 3,500 employees working in around 57 locations across 39 countries. Science, Solutions, Society is our brand promise and how we will achieve our purpose of Transforming Lives Through the Science of Food. By living our purpose we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet. Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2023, Tate & Lyle revenue from continuing operations totalled £1.75 billion. For more information, please visit or follow Tate & Lyle on Twitter, Linkedin, Facebook or YouTube. About Cryptobiotix: Cryptobiotix is a preclinical CRO providing research services in functional foods and therapeutic products, across foodtech, biotech and pharma. It was founded with a focus on researching the interactions between gut modulators, ranging from whole food to specific ingredients like probiotics or APIs. At the heart of their approach, the SIFR® technology (Systemic Intestinal Fermentation Research), a pipeline developed and validated to predict in the lab how individuals would react in real life. Additionally, through lab automation, the validated SIFR® pipeline enables an unmatched throughput that helps generate data across individuals for all the investigated products. To support this unique pipeline, Cryptobiotix relies on an empowered team devoted to curiously explore the world of the gut microbiome, taking the path less travelled, while maintaining the highest industry and deontological standards. At preclinical stage, they address two key elements: the discovery of lead products and the unravelling their mechanism of action. They achieve this through tailor-made experimental design, analytics across omics and host-microbiome interactions as well as compelling preclinical storytelling. From early R&D screening to in-depth characterisation, Cryptobiotix addresses specific research questions and provides the answers to accelerate and de-risk gut health product development. For more information, please visit or follow Cryptobiotix on Linkedin SOURCE Tate & Lyle North America